Cancer-related transcription regulator protein NAC1 forms a protein complex with CARM1 for ovarian cancer progression

Naomi Nakayama; Gyosuke Sakashita; Yuko Nariai; Hiroaki Kato; Kaori Sinmyozu; Jun-Ichi Nakayama; Satoru Kyo; Takeshi Urano; Kentaro Nakayama

doi:10.18632/oncotarget.25400

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Cancer-related transcription regulator protein NAC1 forms a protein complex with CARM1 for ovarian cancer progression

Naomi Nakayama, Gyosuke Sakashita, Yuko Nariai, Hiroaki Kato, Kaori Sinmyozu, Jun-Ichi Nakayama, Satoru Kyo, Takeshi Urano and Kentaro Nakayama _

PDF | HTML | How to cite

Oncotarget. 2018; 9:28408-28420. https://doi.org/10.18632/oncotarget.25400

Metrics: PDF 1854 views | HTML 2631 views | ?

Abstract

Naomi Nakayama1, Gyosuke Sakashita1, Yuko Nariai1, Hiroaki Kato1, Kaori Sinmyozu3,5, Jun-ichi Nakayama4, Satoru Kyo2, Takeshi Urano1 and Kentaro Nakayama2

1Department of Biochemistry, Shimane University School of Medicine, Izumo, Japan

2Department of Obstetrics and Gynecology, Shimane University School of Medicine, Izumo, Japan

3Proteomics Support Unit, RIKEN Center for Developmental Biology, Kobe, Japan

4Graduate School of Natural Sciences, Nagoya City University, Nagoya, Japan

5Current address: National Cerebral and Cardiovascular Center, Osaka, Japan

Correspondence to:

Kentaro Nakayama, email: [email protected]

Takeshi Urano, email: [email protected]

Keywords: nucleus accumbens-associated protein 1 (NAC1); coactivator-associated arginine methyltransferase 1 (CARM1); protein arginine N-methyltransferase 4 (PRMT4); ovarian cancer

Received: February 01, 2018 Accepted: April 16, 2018 Published: June 19, 2018

ABSTRACT

NAC1 is a cancer-related transcription regulator protein that is overexpressed in various carcinomas, including ovarian, cervical, breast, and pancreatic carcinomas. NAC1 knock-down was previously shown to result in the apoptosis of ovarian cancer cell lines and to rescue their sensitivity to chemotherapy, suggesting that NAC1 may be a potential therapeutic target, but protein complex formation of intranuclear NAC1 in ovarian cancer cells remain poorly understood. In this study, analysis of ovarian cancer cell lysates by fast protein liquid chromatography on a sizing column showed that the NAC1 peak corresponded to an apparent molecular mass of 300–500 kDa, which is larger than the estimated molecular mass (58 kDa) of the protein. Liquid chromatography-tandem mass spectrometry analysis identified CARM1 as interacting with NAC1 in the protein complex. Furthermore, tissue microarray analysis revealed a significant correlation between CARM1 and NAC1 expression levels. Ovarian cancer patients expressing high levels of NAC1 and CARM1 exhibited poor prognosis after adjuvant chemotherapy. Collectively, our results demonstrate that high expression levels of NAC1 and its novel binding partner CARM1 may serve as an informative prognostic biomarker for predicting resistance to chemotherapy for ovarian cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25400

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Cancer-related transcription regulator protein NAC1 forms a protein complex with CARM1 for ovarian cancer progression

Abstract